Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Struggling US genomic medicines company Sangamo Therapeutics (Nasdaq: SGMO) has been offered a lifeline via a licensing deal ...

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an additional $1.4 billion. In return, Lilly ...

Eli Lilly licenses Sangamo's BBB-penetrating AAV capsid for CNS disease with $18M upfront; deal includes option for 4 more ...

Eli Lilly’s stock slipped during a broader market nosedive sparked by Trump’s tariff barrage, but retail traders oddly found ...

S&P 500 E-Mini futures (ESM25) are down -2.33%, andJune Nasdaq 100 E-Mini futures (NQM25) are down -2.71% this morning, ...

S&P 500 E-Mini futures (ESM25) are down -2.33%, andJune Nasdaq 100 E-Mini futures (NQM25) are down -2.71% this morning, ...

Five Below’s stocks faced a heavy downturn, plummeting 27.81% to finish at $58.83. The steep drop coincided with overarching market fears stemming from President Donald Trump's tariff plan, which ...

Digital pathology specialist Paige has been awarded breakthrough device status from the FDA for an artificial intelligence ...

Stock index futures are pointing sharply lower again following yesterday’s selloff on Wall Street. China has retaliated with additional tariffs ...